Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

M. Ridker, Paul; M. Everett, Brendan; D. Pradhan, Aruna; MacFadyen, Jean; H. Solomon, Daniel; Zaharris, Elaine; Mam, Virak; Hasan, Ahmed; Rosenberg, Yves; Iturriaga, Erin; Gupta, Milan; Tsigoulis, Michelle; Verma, Subodh; Clearfield, Michael; Libby, Peter; Z. Goldhaber, Samuel; L. Seagle, Roger; Ofori, Cyril; G. Saklayen, Mohammad; Butman, Samuel; Singh, Narendra; Le May, Michel; F. Bertrand, Olivier; Johnston, James; P. Paynter, Nina; J. Glynn, Robert

doi:10.1056/nejmoa1809798

Public

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Published in New England Journal of Medicine • Nov 10, 2018

Authors:

Paul M. Ridker

Brendan M. Everett

Aruna D. Pradhan

Abstract

BACKGROUND: Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether...

Subject

Methotrexate

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!